Unichem receives US FDA nod for pain killer piroxicam capsule

It will commercialise the product from its Goa plant & source API from its API plant in Roha

Unichem receives US FDA nod for pain killer piroxicam capsule
BS B2B Bureau Mumbai
Last Updated : Apr 18 2017 | 11:33 AM IST
Unichem Laboratories Limited has received ANDA approval from the US Food and Drug Administration (USFDA) for pain killer drug piroxicam capsule (10 mg & 20 mg). The approved product is a generic version of Feldene capsules of Pfizer Inc. 

Piroxicam, a nonsteroidal anti-inflammatory drug (NSAID), is used to relieve some symptoms caused by osteoarthritis (arthrosis, degenerative joint disease), rheumatoid arthritis and ankylosing spondylitis (rheumatism of the spine), such as swelling, stiffness and joint pain.

While Unichem will commercialise the product from its Goa plant, it will source the active pharmaceutical ingredient (API), used to make the formation, from its API plant in Roha (Maharashtra).

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story